Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Nyxoah has announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. CEO Olivier Taelman will participate in a fireside chat, accessible via the company's investor relations website. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA), with its lead product, the Genio® system, receiving a European CE Mark in 2019. The company is also conducting the DREAM IDE pivotal study for FDA approval to advance its offerings in the U.S.

Positive

• Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference enhances investor visibility.
• Successful completion of the BLAST OSA study supports the credibility of the Genio® system.
• Genio® system received CE Mark approval, allowing for market entry in Europe.
• Recent positive outcomes from the BETTER SLEEP study expand treatment indications for CCC patients.

Negative

• None.

Nyxoah Announces Participation in the Piper Sandler 33^rd Annual Virtual Healthcare Conference

Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33^rd Annual Virtual Healthcare Conference on from November 22 to December 2, 2021.

A webcast of the Company’s fireside chat will be available on the Company’s investor relations website at https://investors.nyxoah.com/

Nyxoah is participating in investor 1x1 meetings, which can be requested through Piper Sandler.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications 
jeremy.feffer@nyxoah.com
+1 917 749 1494

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment

• ENGLISH - NYXH Announces Piper HC 2021

FAQ

What is Nyxoah's participation in the Piper Sandler Healthcare Conference?

Nyxoah will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021.

What is the Genio® system by Nyxoah?

The Genio® system is a leadless, battery-free hypoglossal neurostimulation therapy for treating Obstructive Sleep Apnea.

When did the Genio® system receive CE Mark approval?

The Genio® system received its European CE Mark in 2019.

What is the current study Nyxoah is conducting for U.S. market approval?

Nyxoah is conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.